series-c-plus
Stage
3
Investors
About
Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics that silence disease-causing genes to treat both rare and prevalent diseases.
Explore Alnylam Pharmaceuticals's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.